title: Optimalization of the clinical pharmacogenetic model to predict methotrexate treatment response: the influence of the number of haplotypes of MTHFR 1298A-677C alleles on probability to respond.
authors: W M
authors: WM
authors: Kooloos
authors: J A M
authors: JA
authors: Wessels
authors: S M
authors: SM
authors: van der Kooij
authors: C F
authors: CF
authors: Allaart
authors: T W J
authors: TW
authors: Huizinga
authors: H-J
authors: HJ
authors: Guchelaar
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D006239:Haplotypes / Q000235:genetics*; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use*; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics*; D008957:Models, Genetic; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D018501:Antirheumatic Agents; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D008727:Methotrexate